Clinical Trial Update: A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis [Phase 1]

View source ↗

Summary

Phase I study of CT-P13 subcutaneous in active Crohn's disease and ulcerative colitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Ulcerative Colitis

Drugs mentioned

• CT-P13 (infliximab biosimilar)

Snippet

Sponsor: Celltrion | Conditions: Crohn's Disease, Ulcerative Colitis (Part 2 Only) | Phase 1 | Status: COMPLETED | Results posted: 2020-06-09